Form 4: BioMarin Pharmaceutical Director Jean-Jacques Bienaime Reports Stock Transaction
SEC Form 4 Filing
Director Jean-Jacques Bienaime reports disposition of BioMarin Pharmaceutical stock to cover tax obligations.
Summary
- On March 15, 2024, Jean-Jacques Bienaime, a director at BioMarin Pharmaceutical Inc., disposed of 85,209 shares of common stock to cover tax obligations.
- The transaction was executed at a price of $83.87 per share.
- Following the transaction, Bienaime directly owns 474,994 shares of BioMarin common stock.
- Bienaime also indirectly owns 247,333 shares through the Jean-Jacques Bienaime Family Trust.
- Additionally, Bienaime holds 100 shares each as UTMA custodian for two children.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard transaction disclosure.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the sale of shares by a director, but it's likely viewed as a routine event.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of stock transaction |
| 03/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.